Nature Communications (Jan 2020)
Preclinical development of a miR-132 inhibitor for heart failure treatment
- Ariana Foinquinos,
- Sandor Batkai,
- Celina Genschel,
- Janika Viereck,
- Steffen Rump,
- Mariann Gyöngyösi,
- Denise Traxler,
- Martin Riesenhuber,
- Andreas Spannbauer,
- Dominika Lukovic,
- Natalie Weber,
- Katrin Zlabinger,
- Ena Hašimbegović,
- Johannes Winkler,
- Jan Fiedler,
- Seema Dangwal,
- Martin Fischer,
- Jeanne de la Roche,
- Daniel Wojciechowski,
- Theresia Kraft,
- Rita Garamvölgyi,
- Sonja Neitzel,
- Shambhabi Chatterjee,
- Xiaoke Yin,
- Christian Bär,
- Manuel Mayr,
- Ke Xiao,
- Thomas Thum
Affiliations
- Ariana Foinquinos
- Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School
- Sandor Batkai
- Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School
- Celina Genschel
- Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School
- Janika Viereck
- Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School
- Steffen Rump
- CARDIOR Pharmaceuticals GmbH
- Mariann Gyöngyösi
- Division of Cardiology, Medical University of Vienna
- Denise Traxler
- Division of Cardiology, Medical University of Vienna
- Martin Riesenhuber
- Division of Cardiology, Medical University of Vienna
- Andreas Spannbauer
- Division of Cardiology, Medical University of Vienna
- Dominika Lukovic
- Division of Cardiology, Medical University of Vienna
- Natalie Weber
- Institute of Molecular and Cell Physiology, Hannover Medical School
- Katrin Zlabinger
- Division of Cardiology, Medical University of Vienna
- Ena Hašimbegović
- Division of Cardiology, Medical University of Vienna
- Johannes Winkler
- Division of Cardiology, Medical University of Vienna
- Jan Fiedler
- Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School
- Seema Dangwal
- Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School
- Martin Fischer
- Institute for Neurophysiology, Hannover Medical School
- Jeanne de la Roche
- Institute for Neurophysiology, Hannover Medical School
- Daniel Wojciechowski
- Institute for Neurophysiology, Hannover Medical School
- Theresia Kraft
- Institute of Molecular and Cell Physiology, Hannover Medical School
- Rita Garamvölgyi
- Department of Diagnostic Imaging and Oncoradiology, University of Kaposvár
- Sonja Neitzel
- Axolabs GmbH
- Shambhabi Chatterjee
- Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School
- Xiaoke Yin
- The James Black Centre, King’s College, University of London
- Christian Bär
- Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School
- Manuel Mayr
- The James Black Centre, King’s College, University of London
- Ke Xiao
- Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School
- Thomas Thum
- Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School
- DOI
- https://doi.org/10.1038/s41467-020-14349-2
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 10
Abstract
miR-132 was shown to drive pathological cardiac remodeling, a hallmark of heart failure. Here, the authors show that an antisense inhibitor of miR-132 has favourable pharmacokinetics, safety-tolerability and preclinical efficacy in mouse and porcine models of heart failure.
